Acadia Pharmaceuticals ACAD Payments to Acquire Intangible Assets

Payments to Acquire Intangible Assets at other companies

BiogenBIIB

——

PTC TherapeuticsPTCT

——

BridgeBio PharmaBBIO

——

Amneal Pharmaceuticals, Inc.AMRX

——

Jazz PharmaceuticalsJAZZ

——

Travere Therapeutics, Inc.TVTX

——

Other financials

Income statement

See full

Revenue$268.1M+9.7%

Gross profit$243.3M+8.6%

Operating income-$4.6M-124%

Net income$3.6M-80.8%

EPS (diluted)$0.02-81.8%

Balance sheet

See full

Cash & equivalents$282.2M+29.6%

Total debt$50.8M-9.3%

Total equity$1.2B+63.1%

Total assets$1.6B+41.8%

Cash flow

See full

Operating cash flow$34.0M+67.2%

CapEx$5.2M—

Free cash flow$28.8M+41.6%

Valuation

See full

Market cap$3.87B+37.0%

Profitability

See full

Gross margin91.5%-0.6pp

Operating margin7.4%-16.2pp

Net margin34.3%+11.3pp

FCF margin18.9%—

Returns & leverage

See full

Return on equity37.3%+0.1pp

Debt / equity0×0.0×

Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's payments to acquire intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Acadia Pharmaceuticals's payments to acquire intangible assets?: Acadia Pharmaceuticals (ACAD) reported payments to acquire intangible assets of $0 in Q1 2026.
How has Acadia Pharmaceuticals's payments to acquire intangible assets changed year-over-year?: Acadia Pharmaceuticals's payments to acquire intangible assets decreased by 100.0% year-over-year, from $98.84M to $0.